Indigestion Medicine Manufacturing OTC in European Union: Market Size, Businesses & Forecast 2026

The over-the-counter (OTC) indigestion medicine manufacturing industry in the European Union focuses on producing non-prescription remedies for gastrointestinal distress, including antacids, proton pump inhibitors, and H2 blockers. The sector forms a critical component of the broader consumer healthcare landscape, which achieved total European value sales of 75.2 billion EUR in 2022 according to the Association of the European Self-Care Industry (AESGP). Driven by increasing consumer proactive management of gut health and shifting demographics, European consumers purchased approximately 8.5 billion packs of non-prescription products in 2022 (AESGP) to alleviate minor ailments like heartburn

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Indigestion Medicine Manufacturing OTC in European Union industry cover?

This industry encompasses the formulation, processing, and packaging of non-prescription (OTC) medications intended to alleviate indigestion, heartburn, acid reflux, and general gastric discomfort. Under the European Union's statistical classification system, these manufacturing activities are situated within the broader production of pharmaceutical preparations.

• •Classified under NACE Rev. 2 code 21.20 for the manufacture of pharmaceutical preparations.
• •Product scope includes chemical antacids (such as calcium carbonate and sodium bicarbonate), H2 receptor antagonists, and proton pump inhibitors (PPIs) cleared for direct consumer purchase.
• •Excludes the production of herbal teas or non-medicinal digestive supplements, which fall under separate food product NACE codes.

Who operates in the industry and how is it structured?

The European manufacturing framework for OTC digestive remedies consists of a mix of multinational pharmaceutical conglomerates and specialized regional manufacturers. Production facilities are highly concentrated in Western European member states, utilizing automated line setups to satisfy rigid chemical consistency mandates.

• •More than 2,000 consumer healthcare enterprises operate across Europe, encompassing both large corporations and small-to-medium enterprises (AESGP 2022).
• •Key production hubs are heavily centered in primary manufacturing nations like Germany, Italy, and France, which generate the majority of total EU industrial output.
• •Distribution relies on dual supply chains targeting traditional brick-and-mortar community pharmacies and rapidly expanding European e-pharmacy networks.

What drives demand in the industry?

Demand for over-the-counter indigestion medicines is strongly correlated with shifting consumer lifestyle habits, aging demographic segments, and increasing public focus on gastrointestinal wellness. Additionally, structural changes in healthcare accessibility act as an indirect catalyst for the expansion of self-care markets.

• •Rising incidents of gastroesophageal reflux disease (GERD) and acute dyspepsia are tied directly to changing dietary patterns across EU member states.
• •Delays or structural backlogs in primary healthcare access increase consumer reliance on immediate OTC self-medication options (European Health Interview Survey).
• •Public health frameworks increasingly encourage individual management of minor gastrointestinal symptoms to lower overall operational strains on national healthcare budgets.

Who are the notable companies in the industry?

The manufacturing landscape is highly competitive and led by established multinational entities that maintain expansive production networks throughout the European Union. These operators leverage robust brand equity and diverse product portfolios containing distinct chemical mechanisms like alginates, carbonates, and systemic acid reducers.

• •Reckitt Benckiser Group plc handles extensive manufacturing operations in Europe for its leading alginate-based brand, Gaviscon.
• •Bayer AG is a primary regional producer of carbonate-based antacids, notably via its legacy brand, Rennie.
• •Sanofi SA manufactures well-known gastric treatments, including the long-standing co-formulated antacid brand, Maalox.
• •Haleon plc manages substantial consumer health manufacturing facilities in the EU, producing widely distributed digestive remedies like Eno.

What are the recent trends and outlook?

The industry is experiencing a notable expansion driven by heightened consumer awareness regarding systemic gut health and microbiome integrity. Manufacturers are responding by actively updating product portfolios to bridge the gap between traditional chemical antacids and preventative gastrointestinal solutions.

• •Digestive health categories are driving a significant portion of value growth within the global and European OTC pharmaceutical landscape (IQVIA Consumer Health 2024).
• •Product innovation is increasingly focusing on multi-symptom relief tablets and rapid-dissolve effervescent formats tailored for on-the-go consumer demographics.
• •Manufacturers face expanding input costs stemming from green packaging mandates and strict environmental supply chain requirements across the EU.

How is the industry regulated?

Operators must comply with strict regulatory frameworks governing safety, formulation integrity, and manufacturing environment standards within the European Single Market. The transition of active ingredients from prescription-only status to OTC retail represents a primary focus of regulatory strategy.

• •Manufacturing plants must strictly adhere to European Union Good Manufacturing Practice (GMP) guidelines under the oversight of national competent authorities.
• •The European Medicines Agency (EMA) collaborates with national bodies to regulate product switches, legal classifications, and active pharmaceutical ingredient safety profiles.
• •Strict European rules govern the marketing, labeling, and permissible health claims allowed on OTC packaging to ensure consumer safety and avoid misleading indications.

Government, statistical and trade sources used for this Claight analysis.

• Association of the European Self-Care Industry (AESGP) Market Data Report 2022 ·
• Eurostat Statistical Classification of Economic Activities in the European Community (NACE Rev. 2) ·
• European Medicines Agency (EMA) Regulatory Framework for OTC Medicines ·
• European Health Interview Survey (EHIS) via Eurostat